|
|
|
29.12.25 - 08:30
|
Dividenden-Garant Sanofi: Milliarden-Deal an Weihnachten (Der Aktionaer)
|
|
|
Der französische Pharma-Konzern Sanofi bleibt aktiv in Sachen Übernahmen. An Heiligabend kündigte die Gesellschaft die milliardenschwere Akquisition von Dynavax Technologies an, womit das Impfstoff-Business verstärkt werden soll. Die Transaktion will die Gesellschaft mit vorhandenen Barmitteln stemmen....
|
|
|
|
|
|
|
|
|
25.12.25 - 09:21
|
Dynavax Technologies (DVAX) Shares Are Trending Overnight — Here′s Why (Benzinga)
|
|
|
Dynavax Technologies shares jumped more than 38% Wednesday after Sanofi announced a $15.50-per-share acquisition offer, valuing the company at roughly $2.2 billion.
Latest Ratings for GS
DateFirmActionFromTo Feb 2022Wells FargoDowngradesOverweightEqual-Weight Feb 2022Morgan StanleyMaintainsEqual-Weight Jan 2022Odeon CapitalDowngradesBuyHold
View More Analyst Ratings for GS
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.12.25 - 16:48
|
Intel Declines; Dynavax Rallies; Nike Ticks Higher (Bloomberg)
|
|
|
- Shares of Intel (INTC) fell in the early session after Reuters reported that Nvidia halted a test that uses the chip manufacturer's 18A technology to produce its chips.
- Shares of Dynavax Technologies (DVAX) soared in premarket trading after Sanofi agreed to buy Dynavax for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm's closing price Tuesday.
- Shares of Nike (NKE) moved higher ahead of the US market open after a filing shows that Apple CEO Tim Cook purchased $2.95 million worth of shares on December 22nd. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
24.12.25 - 10:30
|
Sanofi to Buy Dynavax to Boost Vaccines Business (Bloomberg)
|
|
|
Sanofi agreed to buy Dynavax for about $2.2 billion, as the French drugmaker tries to expand a vaccines business currently anchored by its flu shot franchise. The announcement came after the US Food and Drug Administration surprisingly rejected Sanofi's experimental multiple sclerosis drug tolebrutinib. Bloomberg's Ashleigh Furlong reports. (Source: Bloomberg)...
|
|
|
|
|
|